A citation-based method for searching scientific literature

Orrin Devinsky, J Helen Cross, Linda Laux, Eric Marsh, Ian Miller, Rima Nabbout, Ingrid E Scheffer, Elizabeth A Thiele, Stephen Wright. N Engl J Med 2017
Times Cited: 569







List of co-cited articles
963 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Orrin Devinsky, Anup D Patel, J Helen Cross, Vicente Villanueva, Elaine C Wirrell, Michael Privitera, Sam M Greenwood, Claire Roberts, Daniel Checketts, Kevan E VanLandingham,[...]. N Engl J Med 2018
307
46

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Elizabeth A Thiele, Eric D Marsh, Jacqueline A French, Maria Mazurkiewicz-Beldzinska, Selim R Benbadis, Charuta Joshi, Paul D Lyons, Adam Taylor, Claire Roberts, Kenneth Sommerville. Lancet 2018
323
41

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Orrin Devinsky, Anup D Patel, Elizabeth A Thiele, Matthew H Wong, Richard Appleton, Cynthia L Harden, Sam Greenwood, Gilmour Morrison, Kenneth Sommerville. Neurology 2018
164
24

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Orrin Devinsky, Eric Marsh, Daniel Friedman, Elizabeth Thiele, Linda Laux, Joseph Sullivan, Ian Miller, Robert Flamini, Angus Wilfong, Francis Filloux,[...]. Lancet Neurol 2016
425
22

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez-Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Vincenzo Di Marzo, Didier Jutras-Aswad, William George Notcutt,[...]. Epilepsia 2014
423
21

Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome.
Joshua S Kaplan, Nephi Stella, William A Catterall, Ruth E Westenbroek. Proc Natl Acad Sci U S A 2017
144
20

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
Ian Miller, Ingrid E Scheffer, Boudewijn Gunning, Rocio Sanchez-Carpintero, Antonio Gil-Nagel, M Scott Perry, Russell P Saneto, Daniel Checketts, Eduardo Dunayevich, Volker Knappertz. JAMA Neurol 2020
45
42

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.
Orrin Devinsky, Rima Nabbout, Ian Miller, Linda Laux, Marta Zolnowska, Stephen Wright, Claire Roberts. Epilepsia 2019
77
23

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Lieven Lagae, Joseph Sullivan, Kelly Knupp, Linda Laux, Tilman Polster, Marina Nikanorova, Orrin Devinsky, J Helen Cross, Renzo Guerrini, Dinesh Talwar,[...]. Lancet 2019
71
25

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.
Alexandra L Geffrey, Sarah F Pollack, Patricia L Bruno, Elizabeth A Thiele. Epilepsia 2015
249
14

Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel.
Elaine C Wirrell, Linda Laux, Elizabeth Donner, Nathalie Jette, Kelly Knupp, Mary Anne Meskis, Ian Miller, Joseph Sullivan, Michelle Welborn, Anne T Berg. Pediatr Neurol 2017
103
13

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Rima Nabbout, Arun Mistry, Sameer Zuberi, Nathalie Villeneuve, Antonio Gil-Nagel, Rocio Sanchez-Carpintero, Ulrich Stephani, Linda Laux, Elaine Wirrell, Kelly Knupp,[...]. JAMA Neurol 2020
41
31

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
Elizabeth Thiele, Eric Marsh, Maria Mazurkiewicz-Beldzinska, Jonathan J Halford, Boudewijn Gunning, Orrin Devinsky, Daniel Checketts, Claire Roberts. Epilepsia 2019
44
25

The core Dravet syndrome phenotype.
Charlotte Dravet. Epilepsia 2011
262
11

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
José Alexandre S Crippa, Guilherme Nogueira Derenusson, Thiago Borduqui Ferrari, Lauro Wichert-Ana, Fábio L S Duran, Rocio Martin-Santos, Marcus Vinícius Simões, Sagnik Bhattacharyya, Paolo Fusar-Poli, Zerrin Atakan,[...]. J Psychopharmacol 2011
236
11

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Penny F Whiting, Robert F Wolff, Sohan Deshpande, Marcello Di Nisio, Steven Duffy, Adrian V Hernandez, J Christiaan Keurentjes, Shona Lang, Kate Misso, Steve Ryder,[...]. JAMA 2015
940
10

Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Linda C Laux, E Martina Bebin, Daniel Checketts, Michael Chez, Robert Flamini, Eric D Marsh, Ian Miller, Kathryn Nichol, Yong Park, Eric Segal,[...]. Epilepsy Res 2019
48
20

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.
R B Laprairie, A M Bagher, M E M Kelly, E M Denovan-Wright. Br J Pharmacol 2015
406
10

Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.
Fabio Arturo Iannotti, Charlotte L Hill, Antonio Leo, Ahlam Alhusaini, Camille Soubrane, Enrico Mazzarella, Emilio Russo, Benjamin J Whalley, Vincenzo Di Marzo, Gary J Stephens. ACS Chem Neurosci 2014
192
10

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.
C Chiron, M C Marchand, A Tran, E Rey, P d'Athis, J Vincent, O Dulac, G Pons. Lancet 2000
327
10

ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.
Ingrid E Scheffer, Samuel Berkovic, Giuseppe Capovilla, Mary B Connolly, Jacqueline French, Laura Guilhoto, Edouard Hirsch, Satish Jain, Gary W Mathern, Solomon L Moshé,[...]. Epilepsia 2017
10

Cannabinoids in treatment-resistant epilepsy: A review.
Brooke K O'Connell, David Gloss, Orrin Devinsky. Epilepsy Behav 2017
106
9

Interactions between cannabidiol and commonly used antiepileptic drugs.
Tyler E Gaston, E Martina Bebin, Gary R Cutter, Yuliang Liu, Jerzy P Szaflarski. Epilepsia 2017
153
9


Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.
Lyndsey L Anderson, Nathan L Absalom, Sarah V Abelev, Ivan K Low, Peter T Doohan, Lewis J Martin, Mary Chebib, Iain S McGregor, Jonathon C Arnold. Epilepsia 2019
42
21



Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
Mateus M Bergamaschi, Regina Helena Costa Queiroz, Marcos Hortes Nisihara Chagas, Danielle Chaves Gomes de Oliveira, Bruno Spinosa De Martinis, Flávio Kapczinski, João Quevedo, Rafael Roesler, Nadja Schröder, Antonio E Nardi,[...]. Neuropsychopharmacology 2011
321
9

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
Philip McGuire, Philip Robson, Wieslaw Jerzy Cubala, Daniel Vasile, Paul Dugald Morrison, Rachel Barron, Adam Taylor, Stephen Wright. Am J Psychiatry 2018
207
9

Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
Luciano De Petrocellis, Alessia Ligresti, Aniello Schiano Moriello, Marco Allarà, Tiziana Bisogno, Stefania Petrosino, Colin G Stott, Vincenzo Di Marzo. Br J Pharmacol 2011
419
9


Successful use of fenfluramine as an add-on treatment for Dravet syndrome.
Berten Ceulemans, Marc Boel, Katrien Leyssens, Carolin Van Rossem, Pieter Neels, Philippe G Jorens, Lieven Lagae. Epilepsia 2012
101
9


Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities.
Dana Barchel, Orit Stolar, Tal De-Haan, Tomer Ziv-Baran, Naama Saban, Danny Or Fuchs, Gideon Koren, Matitiahu Berkovitch. Front Pharmacol 2019
45
17

Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Jerzy P Szaflarski, Elizabeth Martina Bebin, Anne M Comi, Anup D Patel, Charuta Joshi, Daniel Checketts, Jules C Beal, Linda C Laux, Lisa M De Boer, Matthew H Wong,[...]. Epilepsia 2018
89
8


Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
T Bisogno, L Hanus, L De Petrocellis, S Tchilibon, D E Ponde, I Brandi, A S Moriello, J B Davis, R Mechoulam, V Di Marzo. Br J Pharmacol 2001
666
8

Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
Simona Lattanzi, Eugen Trinka, Pasquale Striano, Gaetano Zaccara, Cinzia Del Giovane, Raffaele Nardone, Mauro Silvestrini, Francesco Brigo. Epilepsia 2020
25
32

The proposed mechanisms of action of CBD in epilepsy.
Royston A Gray, Benjamin J Whalley. Epileptic Disord 2020
22
36

Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
J M Cunha, E A Carlini, A E Pereira, O L Ramos, C Pimentel, R Gagliardi, W L Sanvito, N Lander, R Mechoulam. Pharmacology 1980
305
8

Agonistic properties of cannabidiol at 5-HT1a receptors.
Ethan B Russo, Andrea Burnett, Brian Hall, Keith K Parker. Neurochem Res 2005
418
8

The case for medical marijuana in epilepsy.
Edward Maa, Paige Figi. Epilepsia 2014
135
8

Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
Nicholas A Jones, Andrew J Hill, Imogen Smith, Sarah A Bevan, Claire M Williams, Benjamin J Whalley, Gary J Stephens. J Pharmacol Exp Ther 2010
187
8

Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish.
Jo Sourbron, Ilse Smolders, Peter de Witte, Lieven Lagae. Front Pharmacol 2017
55
14

Inhibitory effects of cannabidiol on voltage-dependent sodium currents.
Mohammad-Reza Ghovanloo, Noah Gregory Shuart, Janette Mezeyova, Richard A Dean, Peter C Ruben, Samuel J Goodchild. J Biol Chem 2018
55
12

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
Jerzy P Szaflarski, Elizabeth Martina Bebin, Gary Cutter, Jennifer DeWolfe, Leon S Dure, Tyler E Gaston, Pongkiat Kankirawatana, Yuliang Liu, Rani Singh, David G Standaert,[...]. Epilepsy Behav 2018
66
10

Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
Simona Lattanzi, Francesco Brigo, Eugen Trinka, Gaetano Zaccara, Claudia Cagnetti, Cinzia Del Giovane, Mauro Silvestrini. Drugs 2018
79
8

Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Orrin Devinsky, Chloe Verducci, Elizabeth A Thiele, Linda C Laux, Anup D Patel, Francis Filloux, Jerzy P Szaflarski, Angus Wilfong, Gary D Clark, Yong D Park,[...]. Epilepsy Behav 2018
59
11

Hashish. I. The structure of cannabidiol.
R Mechoulam, Y Shvo. Tetrahedron 1963
217
7

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon. Molecules 2019
51
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.